Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society（2023）
摘要
■■■■.
更多查看译文
关键词
liver transplant patients,hepatocellular carcinoma,nivolumab/bevacizumab,second-line
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要